Table 1.
Summary of results of clinical trials of 5-azacytidine in MDS
CMML indicates chronic myelomonocytic leukemia; SC, subcutaneously; ND, not described; PR, partial remission; HI, hematologic improvement; ORR, overall response rate (CR + PR + HI); Cyto, cytogenetic response; and SD, stable disease.
*Dysplasia possible.
†Not IWG criteria.
